BAUSCH AND LOMB INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAUSCH AND LOMB INC, and when can generic versions of BAUSCH AND LOMB INC drugs launch?
BAUSCH AND LOMB INC has nineteen approved drugs.
There are thirty-two US patents protecting BAUSCH AND LOMB INC drugs.
There are three hundred and seventy-four patent family members on BAUSCH AND LOMB INC drugs in thirty-one countries and forty-one supplementary protection certificates in fourteen countries.
Summary for BAUSCH AND LOMB INC
| International Patents: | 374 |
| US Patents: | 32 |
| Tradenames: | 19 |
| Ingredients: | 15 |
| NDAs: | 19 |
| Drug Master File Entries: | 1 |
Drugs and US Patents for BAUSCH AND LOMB INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 7,745,460 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
| Bausch And Lomb Inc | MIEBO | perfluorohexyloctane | SOLUTION/DROPS;OPHTHALMIC | 216675-001 | May 18, 2023 | RX | Yes | Yes | 10,058,615 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Bausch And Lomb Inc | BEPREVE | bepotastine besilate | SOLUTION/DROPS;OPHTHALMIC | 022288-001 | Sep 8, 2009 | AT | RX | Yes | Yes | 8,784,789 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 8,592,450 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch And Lomb Inc | XIIDRA | lifitegrast | SOLUTION/DROPS;OPHTHALMIC | 208073-001 | Jul 11, 2016 | AB | RX | Yes | Yes | 10,124,000 | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Bausch And Lomb Inc | LUMIFY | brimonidine tartrate | SOLUTION/DROPS;OPHTHALMIC | 208144-001 | Dec 22, 2017 | OTC | Yes | Yes | 9,259,425 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAUSCH AND LOMB INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | XIBROM | bromfenac sodium | SOLUTION/DROPS;OPHTHALMIC | 021664-001 | Mar 24, 2005 | 4,910,225 | ⤷ Try a Trial |
| Bausch And Lomb Inc | TIMOPTIC-XE | timolol maleate | SOLUTION, GEL FORMING/DROPS;OPHTHALMIC | 020330-001 | Nov 4, 1993 | 4,195,085 | ⤷ Try a Trial |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | 6,147,204 | ⤷ Try a Trial |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | 5,932,462 | ⤷ Try a Trial |
| Bausch And Lomb Inc | TIMOPTIC | timolol maleate | SOLUTION/DROPS;OPHTHALMIC | 018086-001 | Approved Prior to Jan 1, 1982 | 3,655,663 | ⤷ Try a Trial |
| Bausch And Lomb Inc | MACUGEN | pegaptanib sodium | INJECTABLE;INTRAVITREAL | 021756-001 | Dec 17, 2004 | 6,011,020 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for BAUSCH AND LOMB INC drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 1.5% | ➤ Subscribe | 2013-09-09 |
International Patents for BAUSCH AND LOMB INC Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 708821 | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2017220625 | ⤷ Try a Trial |
| Japan | 5105578 | ⤷ Try a Trial |
| Israel | 242395 | ⤷ Try a Trial |
| Japan | 2018507252 | ⤷ Try a Trial |
| China | 109640900 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for BAUSCH AND LOMB INC Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2444079 | C02444079/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: NOVARTIS AG, CH |
| 0957929 | SZ 20/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: PEGAPTANIB UND SALZE DAVON |
| 1586316 | SPC/GB11/054 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
| 3043773 | 301154 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426 |
| 2826776 | LUC00207 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF (A) (R)-1-(2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)-N-(1-(2,3-DIHYDROXYPROPYL)-6-FLUORO-2-(1-HYDROXY-2-METHYLPROPAN-2-YL)-1H-INDOL-5-YL)CYCLOPROPANECARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND (B) N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/18/1306 20181106 |
| 0509752 | 2000C/001 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
